Results 101 to 110 of about 10,898,286 (409)

Corporate Social Responsibility Disclosure and Firm Financial Performance in Mining and Natural Resources Industry [PDF]

open access: yes, 2014
Business operations nowadays should not only pursue profits, but also contribute positively to the society as well as environment. This is because people currently have become more critical to the need of social control over the business.
Dayanti, N. (Nadia)   +1 more
core  

A literature review of the history and evolution of corporate social responsibility

open access: yesInternational Journal of Corporate Social Responsibility, 2019
There is a long and varied history associated with the evolution of the concept of Corporate Social Responsibility (CSR). However, a historical review is missing in the academic literature that portrays the evolution of the academic understanding of the ...
Mauricio Andrés Latapí Agudelo   +2 more
semanticscholar   +1 more source

Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study

open access: yesMolecular Oncology, EarlyView.
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima   +6 more
wiley   +1 more source

Stakeholders’ Contribution towards Responsible Innovation in Information and Communication Technology Research Projects

open access: yesJournal of Technology Management & Innovation, 2019
Information and Communication Technology (ICT) research projects engage stakeholders who contribute towards different aspects of research and innovation.
Tilimbe Jiya
doaj   +1 more source

The impact of social responsibility on corporate financial performance: A systematic literature review

open access: yesCorporate Social Responsibility and Environmental Management, 2023
Rui Coelho   +2 more
semanticscholar   +1 more source

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

open access: yesMolecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li   +12 more
wiley   +1 more source

Corrigendum: Towards an understanding of global brain data governance: ethical positions that underpin global brain data governance discourse

open access: yesFrontiers in Big Data, 2023
Paschal Ochang   +3 more
doaj   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

open access: yesMolecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi   +12 more
wiley   +1 more source

Experiments in social responsibility [PDF]

open access: yesNature, 2006
Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry. The Novartis research facility in Singapore, focusing on dengue fever and tuberculosis, reflects a new approach from pharmaceuticals companies ...
openaire   +3 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy